…
comment: The repository administrator has not yet configured an RDF license.
primary topic: Efficacy of liposomal amphotericin B for treating post-kala-azar dermal leishmaniasis (PKDL): A systematic review and single-arm meta-analysis

Efficacy of liposomal amphotericin B for treating post-kala-azar dermal leishmaniasis (PKDL): A systematic review and single-arm meta-analysis
type: AcademicArticle
type: Article
abstract: Background Post-kala-azar dermal leishmaniasis (PKDL) is a skin condition that can become a complication in about 15 % of patients who have had kala-azar. Despite its significance, treatment options for PKDL are still limited. This systematic review and meta-analysis aim to evaluate the efficacy of amphotericin B for this condition. Methods PubMed, Embase, Cochrane, and Web of Science databases were searched for randomized controlled trials (RCTs) that reported the efficacy of Liposomal Amphotericin B in the treatment of PKDL. This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Events per 100 observations with 95 % confidence intervals were performed for outcomes. Results Nine studies with 639 patients were included, the treatment durations ranging from 7 to 60 days. The mean age ranged from 9.2 to 31.0 years, and 359 patients were male. The PKDL treatment with liposomal amphotericin B resulted in a cure rate of 91.36 % (95 % CI: 76.60-97.15). However, a relapse was observed in 11.42 % (95 % CI: 6.20-20.8) of patients. Adverse events were common, with hepatic enzyme elevation (ALT/AST) being the most frequent (61.75 %; 95 % CI: 21.81–90.33), followed by fever in 29.93 % of cases (95 % CI: 5.09–77.30). Among the more serious side effects, decreased serum potassium was observed in 19.27 % (95 % CI: 3.84–58.82), and increased serum creatinine, indicative of nephrotoxicity, occurred in 15.08 % (95 % CI: 3.97–43.27). Nausea or vomiting, although less severe, affected 12.36 % of patients (95 % CI: 4.81–28.25). Conclusions These findings highlight that while liposomal amphotericin B is a potent therapeutic option for PKDL, its administration requires careful management and clinical vigilance to optimize outcomes and minimize risks.
date: 2026-02
volume: 114
issue: 2
is part of: Diagnostic Microbiology and Infectious Disease
status: peerReviewed
status: published
author list: authors
type: EPrint
type: ArticleEPrint
is part of: repository
subject: Biomedicine

Diagnostic Microbiology and Infectious Disease
type: Collection
issn: 07328893

Deivyd Vieira Silva Cavalcante
type: Person
given name: Deivyd Vieira Silva
family name: Cavalcante

Fabiana Castro Porto Silva Lopes
type: Person
given name: Fabiana Castro Porto Silva
family name: Lopes

Lyria de Oliveira Rosa
type: Person
given name: Lyria de Oliveira
family name: Rosa

Noor Husain
type: Person
given name: Noor
family name: Husain

Luciana Borrigueiro
type: Person
given name: Luciana
family name: Borrigueiro

Lilia Maria Lima de Oliveira
type: Person
given name: Lilia Maria Lima
family name: de Oliveira

Sarah Soares Amorim
type: Person
given name: Sarah Soares
family name: Amorim

Ana Clara Felix de Farias Santos
type: Person
given name: Ana Clara Felix de Farias
family name: Santos

Christian Ndikuryayo
type: Person
given name: Christian
family name: Ndikuryayo

Lalit Mohan
type: Person
given name: Lalit
family name: Mohan

Beatriz Ximenes Mendes
type: Person
given name: Beatriz Ximenes
family name: Mendes

HTML Summary of #17868 Efficacy of liposomal amphotericin B for treating post-kala-azar dermal leishmaniasis (PKDL): A systematic review and single-arm meta-analysis
format: text/html
primary topic: Efficacy of liposomal amphotericin B for treating post-kala-azar dermal leishmaniasis (PKDL): A systematic review and single-arm meta-analysis

Biomedicine
type: Concept
preferred label: Biomedicina @es